In this issue of Blood, Giarratana et al. provide an important proof of principle in the quest for biotechnology's equivalent of the Holy Grail of blood transfusion: ex vivo manufacture of human red cells (RBCs) for therapeutic use (see figure).
|Original language||English (US)|
|Number of pages||2|
|State||Published - Nov 10 2011|
ASJC Scopus subject areas
- Cell Biology